8 withdrawn. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Withdrawn 8 |
Follow Sleep Initiation and Maintenance Disorders: new trials by email Literature Review of Sleep Initiation and Maintenance Disorders trials Research Report on Sleep Initiation and Maintenance Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients Best Practice, Electronic Health Record Review, Interview - Advanced Malignant Solid Neoplasm, Delirium | Phase 4 | Withdrawn | Mayo Clinic | 2025-02-26 | 2025-05-01 | |
| Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept Pimavanserin - Insomnia Chronic, Posttraumatic Stress Disorder | Phase 4 | Withdrawn | Baylor College of Medicine | 2022-12-15 | 2023-03-24 | |
| Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults Ramelteon, Placebo - Delirium in Old Age | Phase 4 | Withdrawn | Brigham and Women's Hospital | 2019-12-01 | 2020-01-22 | |
| Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia Suvorexant (Belsomra), Placebo - Bipolar Disorder, Insomnia | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-02-26 | 2021-02-21 | |
| Ramelteon for Complex Insomnia in Veterans With PTSD Ramelteon, Usual Care - Insomnia | Phase 4 | Withdrawn | State University of New York at Buffalo | 2018-01-01 | 2021-04-09 | |
| To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures Perampanel, Placebo - Epilepsy, Partial | Phase 4 | Withdrawn | Eisai Inc. | 2015-03-01 | 2015-02-10 | |
| Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Sodium oxybate, Placebo - Chronic Fatigue Syndrome | Phase 4 | Withdrawn | University Hospital, Ghent | 2013-06-01 | 2022-12-15 | |
| Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects melatonin, placebo - Lennox-Gastaut Syndrome | Phase 4 | Withdrawn | Institution de Lavigny | 2011-08-01 | 2022-07-14 |
Delirium (2) · Stress Disorders, Post-Traumatic (2) · Bipolar Disorder (1) · Bronchiolitis Obliterans Syndrome (1) · Epilepsies, Partial (1) · Epilepsy (1) · Fatigue (1) · Fatigue Syndrome, Chronic (1) · Lennox Gastaut Syndrome (1) · Seizures (1) · Sleep Apnea Syndromes (1)
Dyssomnias (8) · Mental Disorders (8) · Nervous System Diseases (8) · Sleep Disorders, Intrinsic (8) · Sleep Wake Disorders (8) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Neurologic Manifestations (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Confusion (2) · Neurobehavioral Manifestations (2) · Neurocognitive Disorders (2) · Respiratory Tract Diseases (2) · Stress Disorders, Traumatic (2)
ramelteon (2) · suvorexant (2) · Interviews as Topic (1) · Melatonin (1) · Practice Guidelines as Topic (1) · Sodium Oxybate (1) · Standard of Care (1) · perampanel (1) · pimavanserin (1)
Baylor College of Medicine (1) · Brigham and Women's Hospital (1) · Eisai Inc. (1) · Institution de Lavigny (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · State University of New York at Buffalo (1) · University Hospital, Ghent (1)
United States (4) · Belgium (1) · Switzerland (1)
Ali El Solh, MD (1) · An Mariman, MD (1) · Elizabeth B Klerman, M.D.,PhD (1) · Giovanni B. Foletti, MD, MER (1) · Gustavo Kinrys, MD (1) · Melissa B Jones, MD (1) · Regina M. Mackey, MD (1)